JP Morgan Maintains Overweight on Imax, Raises Price Target to $50

Benzinga Newsdesk www.benzinga.com Positive 71.1%

Neg 0% Neu 0% Pos 71.1%

JP Morgan analyst David Karnovsky maintains Imax (NYSE:IMAX) with a Overweight and raises the price target from $47 to $50.